VELCADE (bortezomib) - Caremark
With multiple myeloma and patients with mantle cell lymphoma (1). Velcade is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of Velcade (1). Patients should be monitored for cardiac toxicity, pulmonary toxicity, thrombocytopenia or ... Retrieve Content
No comments:
Post a Comment